Anthem Biosciences IPO Listing: The Anthem Biosciences IPO has been one of the most anticipated events in the Indian stock market this year, and it didn’t disappoint! On July 21, 2025, the shares of Anthem Biosciences Limited, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), made a stellar debut on the BSE and NSE. With a listing price significantly higher than its issue price, investors are buzzing with excitement. Let’s dive into the details of this blockbuster IPO and what it means for the market.
Table of Contents
A Robust Market Debut
Anthem Biosciences’ shares listed at ₹723.05 on the NSE and ₹723.10 on the BSE, reflecting a premium of around 27% over the issue price of ₹570 per share. This strong debut was in line with market expectations, fueled by a high Grey Market Premium (GMP) in the days leading up to the listing. On July 21, the GMP was reported at ₹179, suggesting an estimated listing price of ₹749, though the actual listing was slightly below this mark. Still, a 27% gain is a fantastic outcome for allottees, and posts on X celebrated the success, with users like @Paryan_Sharma and @Tanmay_31_ calling it a “blockbuster” debut. The strong listing reflects investor confidence in Anthem’s growth potential and its solid position in the biotech and pharmaceutical sector.
About Anthem Biosciences
Founded in 2006 and headquartered in Bengaluru, Anthem Biosciences is a powerhouse in the CRDMO space. The company offers end-to-end services, from drug discovery to commercial manufacturing, catering to both small biotech startups and global pharmaceutical giants across 44 countries. Anthem specializes in New Chemical Entities (NCEs) and New Biological Entities (NBEs), with expertise in fermentation-based APIs, peptides, probiotics, and biosimilars. With two operational manufacturing units in Karnataka and a third under construction, Anthem is expanding its fermentation capacity to 182 kL by mid-FY26. Its client base of over 550, including partnerships with companies like Bayer AG, underscores its global reach and reputation.
IPO Details and Subscription Frenzy
The Anthem Biosciences IPO, a ₹3,395 crore book-built issue, was entirely an Offer for Sale (OFS) of 5.96 crore equity shares. Open for subscription from July 14 to July 16, 2025, the IPO saw overwhelming demand, getting subscribed 67.42 times. The Qualified Institutional Buyers (QIBs) led the charge with a subscription rate of 192.80 times, followed by Non-Institutional Investors (NIIs) at 44.70 times, and retail investors at 5.98 times. The price band was set at ₹540–₹570 per share, with a minimum lot size of 26 shares, requiring a retail investment of ₹14,820. The allotment was finalized on July 17, and shares were credited to demat accounts on July 18, with refunds processed for unsuccessful bidders.
Financial Strength and Growth Prospects
Anthem Biosciences has shown impressive financial performance, making it an attractive pick for long-term investors. In FY25, the company reported a revenue of ₹1,930.29 crore, a 30% jump from ₹1,483.07 crore in FY24. Its profit after tax (PAT) grew by 23% to ₹451.26 crore from ₹367.31 crore. With a high EBITDA margin of 37% and a focus on high-margin segments like Fee-For-Service contracts, Anthem stands out among its peers. The company’s P/E ratio of 70.9x has raised some concerns about valuation, but its robust growth, low debt, and global client base make it a compelling investment. Anthem’s plans to expand its fermentation capacity and invest in a new greenfield facility under its subsidiary, Neoanthem, signal strong future growth.
What’s Next for Anthem Biosciences?
The successful listing is just the beginning for Anthem Biosciences. The company’s focus on innovation, green chemistry, and a diversified portfolio positions it well in the competitive CRDMO market. However, as a 100% OFS, the IPO proceeds go to the selling shareholders, not the company, which has sparked some debate about its valuation. Investors should also consider risks like regulatory challenges and competition from players like Syngene International. Still, Anthem’s strong fundamentals and global reach make it a stock to watch. For those who missed the IPO, the current market sentiment suggests it could be a solid long-term bet, but as always, do your research before diving in